3/3
10:18 am
sepn
Septerna (SEPN) had its price target raised by Wells Fargo & Company from $28.00 to $48.00. They now have an "overweight" rating on the stock.
Low
Report
Septerna (SEPN) had its price target raised by Wells Fargo & Company from $28.00 to $48.00. They now have an "overweight" rating on the stock.
3/2
01:00 pm
sepn
Septerna (SEPN) had its price target raised by HC Wainwright from $35.00 to $40.00. They now have a "buy" rating on the stock.
Low
Report
Septerna (SEPN) had its price target raised by HC Wainwright from $35.00 to $40.00. They now have a "buy" rating on the stock.
3/1
10:14 am
sepn
Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy [Yahoo! Finance]
Low
Report
Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy [Yahoo! Finance]
3/1
09:45 am
sepn
Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy
Low
Report
Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy
2/26
06:28 am
sepn
Septerna (SEPN) was upgraded by Zacks Research from "strong sell" to "hold".
Low
Report
Septerna (SEPN) was upgraded by Zacks Research from "strong sell" to "hold".
2/24
08:00 am
sepn
Septerna to Present at TD Cowen 46th Annual Health Care Conference
Medium
Report
Septerna to Present at TD Cowen 46th Annual Health Care Conference
2/10
04:05 pm
sepn
Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2/10
08:00 am
sepn
Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual Meeting
Low
Report
Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual Meeting
1/27
05:58 am
sepn
Septerna (NASDAQ:SEPN) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Low
Report
Septerna (NASDAQ:SEPN) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
1/20
07:17 am
sepn
Septerna (NASDAQ:SEPN) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Septerna (NASDAQ:SEPN) had its "buy" rating reaffirmed by analysts at HC Wainwright.
1/10
01:07 am
sepn
Low
Report
1/8
04:17 pm
sepn
Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer [Yahoo! Finance]
Low
Report
Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer [Yahoo! Finance]
1/8
04:05 pm
sepn
Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer
Low
Report
Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer
12/23
09:21 am
sepn
Septerna (NASDAQ:SEPN) is now covered by analysts at Jones Trading. They set a "buy" rating and a $43.00 price target on the stock.
Medium
Report
Septerna (NASDAQ:SEPN) is now covered by analysts at Jones Trading. They set a "buy" rating and a $43.00 price target on the stock.
12/20
07:27 am
sepn
Septerna (NASDAQ:SEPN) was upgraded by analysts at Raymond James Financial, Inc. to a "strong-buy" rating.
Low
Report
Septerna (NASDAQ:SEPN) was upgraded by analysts at Raymond James Financial, Inc. to a "strong-buy" rating.
12/20
01:30 am
sepn
Low
Report
12/19
07:19 am
sepn
Septerna (NASDAQ:SEPN) is now covered by analysts at Raymond James Financial, Inc.. They set a "strong-buy" rating on the stock.
Medium
Report
Septerna (NASDAQ:SEPN) is now covered by analysts at Raymond James Financial, Inc.. They set a "strong-buy" rating on the stock.
12/17
08:00 am
sepn
Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference
12/17
07:26 am
sepn
Septerna (NASDAQ:SEPN) was upgraded by analysts at Truist Financial Corporation to a "strong-buy" rating.
Low
Report
Septerna (NASDAQ:SEPN) was upgraded by analysts at Truist Financial Corporation to a "strong-buy" rating.
12/15
08:43 am
sepn
Septerna (NASDAQ:SEPN) was given a new $34.00 price target on by analysts at Truist Financial Corporation.
Medium
Report
Septerna (NASDAQ:SEPN) was given a new $34.00 price target on by analysts at Truist Financial Corporation.